此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

BATwire Implant Kit Study

2026年9月9日 更新者:CVRx, Inc.

The purpose of this clinical investigation is to develop valid scientific evidence for the safety and effectiveness of the Barostim System delivered by the BATwire Implant Kit (BATwire Kit) in subjects with heart failure. Subjects may be enrolled if they meet the FDA approved PMA indication for use for the Barostim NEO or Barostim NEO2 device: Subjects who remain symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III or Class II (who had a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, a NT-proBNP < 1600 pg/ml and excludes patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.

研究概览

地位

终止

条件

详细说明

The BATwire Implant Kit Study is a prospective study of up to 400 subjects enrolled at up to 35 U.S. sites. Up to 100 subjects will be implanted with the Barostim System using the BATwire Kit after all screening is complete and all enrollment criteria are met. The study will evaluate the implant experience, safety and effectiveness of the BATwire kit.

All subjects will be implanted, and the device will be activated prior to being discharged. Follow-up visits will occur at 0.5, 1, 2, 3, 6 and 12 months post implant. Once the 12-month visit has been completed, the subject is withdrawn from the study and followed in a commercial setting.

研究类型

介入性

注册 (实际的)

93

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Mesa、Arizona、美国、85206
        • Chan Heart Rhythm Institute
      • Scottsdale、Arizona、美国、85258
        • HonorHealth
    • Florida
      • Orlando、Florida、美国、32803
        • AdventHealth
    • Georgia
      • Atlanta、Georgia、美国、30308
        • Emory University
      • Atlanta、Georgia、美国、30309
        • Piedmont Health
    • Missouri
      • St Louis、Missouri、美国、63136
        • St. Louis Heart and Vascular, P.C.
    • North Carolina
      • Greensboro、North Carolina、美国、27401
        • Cone Health
      • Winston-Salem、North Carolina、美国、27157
        • Wake Forest
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • Medical University of South Carolina
    • Texas
      • Austin、Texas、美国、78756
        • Austin Heart

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age at least 21 years and no more than 80 years at the time of enrollment.

  2. Appropriate candidate for the surgery as determined by an evaluation from the implanting physician using a carotid duplex ultrasound (CDU) and/or a computed tomography angiography (CTA), and a review of medical history (including existence of infections that may increase implant risk). Evaluation must confirm the following within 45 days of the Barostim implant (60 days allowed if a proctor is required):

    • Appropriate medical condition and medical history for implantation of the Barostim System AND

    • Anatomy that enables this implant procedure, with no vascular structures or orientations or neck anomalies that would be obstructive to the implantation path AND

    • The artery planned for the Barostim implant must have:

      • A carotid bifurcation below the level of the mandible AND
      • No ulcerative carotid arterial plaques AND
      • No carotid atherosclerosis producing a 30% or greater reduction in linear diameter in the internal carotid AND
      • No carotid atherosclerosis producing a 30% or greater reduction in linear diameter in the distal common carotid AND
    • Have had no prior surgery, radiation, or endovascular stent placement in the carotid artery or the carotid sinus region AND

    • Able to discontinue the use of antiplatelet drugs (e.g., aspirin) in advance of the procedure, if required.

  3. Six-minute hall walk (6MHW) ≥ 150 m AND ≤ 400 m within 45 days prior to implant (60 days allowed if a proctor is required).

  4. Serum estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m^2 using the CKD-EPI method within 45 days prior to the Barostim implant (60 days allowed if a proctor is required).

  5. Body mass index ≤ 40 kg/m^2 within 45 days prior to the Barostim implant (60 days allowed if a proctor is required).

  6. If female and of childbearing potential, must use a medically accepted method of birth control (e.g., barrier method with spermicide, oral contraceptive, or abstinence) and agree to continue use of this method for the duration of the study. Women of childbearing potential must have a negative pregnancy test within 14 days prior to the Barostim implant.

  7. Subjects implanted with a cardiac rhythm management device that does not utilize an intracardiac lead, or implanted with a neurostimulation device, must be approved by the CVRx Clinical department.

  8. At the end of screening and baseline, the subject still meets the Barostim Indication for Use

  9. Signed a CVRx-approved informed consent form for participation in this study.

Exclusion Criteria:

  1. Received cardiac resynchronization therapy (CRT) within six months of enrollment, or is actively receiving CRT.

  2. Any of the following contraindications:

    • Baroreflex failure or autonomic neuropathy
    • Uncontrolled, symptomatic cardiac bradyarrhythmias
    • Known allergy to silicone or titanium
  3. Unstable ventricular arrhythmias.

  4. Presence of baseline cranial nerve dysfunction at risk from cervical interventions on the carotid bifurcation determined by the Ear, Nose and Throat (ENT) examination.

  5. Subjects with any surgery that has occurred, or is planned to occur, within 45 days of the Barostim implant.

  6. Recent history (within 6 months of implant) of significant and uncontrolled bleeding.

  7. Known and untreated hypercoagulability state.

  8. An inappropriate study candidate as evidenced by:

    • Solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
    • Has received or is receiving LVAD therapy or chronic dialysis.
    • Current or planned treatment with intravenous positive inotrope therapy.
    • Primary pulmonary hypertension.
    • Severe COPD or severe restrictive lung disease (e.g., requires chronic oral steroid use or home oxygen use).
    • Heart failure secondary to a reversible cause, such as cardiac structural valvular disease, acute myocarditis and pericardial constriction.
    • Clinically significant cardiac structural valvular disease.
    • Unable or unwilling to fulfill the protocol medication compliance and follow-up requirements, for reasons including but not limited to an unresolved history of alcohol or substance abuse or psychiatric disorder.
    • Active malignancy.
    • Any other serious medical condition that may adversely affect the safety of the participant or validity of the study, in the opinion of the investigator.
    • Life expectancy less than one year.
  9. Any of the following within 3 months prior to the Barostim implant.

    • Myocardial infarction
    • Unstable angina
    • Percutaneous coronary intervention (e.g., CABG or PTCA)
    • Cerebral vascular accident or transient ischemic attack
    • Sudden cardiac death
    • Surgical cardiac intervention (e.g., cardiac ablation, valve replacement)
  10. Enrolled and active in another (e.g., device, pharmaceutical, or biological) clinical study unless approved by the CVRx Clinical department.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:BATwire Kit

Subjects will be implanted using the BATwire Implant Kit

The BATwire Implant Kit is a delivery system for the placement of the Barostim Carotid Sinus Lead.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants Without Serious Adverse Events (SAEs) Related to the Implantation of the Lead Using the BATwire Implant Kit Through 30 Days Post-implant.
大体时间:30 days post-implant

To demonstrate the safety of implanting the Barostim lead using the BATwire Implant Kit using all serious adverse events that are related to the BATwire lead implantation that occur between implant, or attempted implant, and 30 days post implant.

30 days post-implant
Change in Six Minute Hall Walk (6MHW) Distance Walked
大体时间:From baseline to 6 months of follow-up, post-implant

To demonstrate that treatment with the Barostim System implanted using the BATwire Implant Kit results in an improvement in 6MHW at 6 months.

From baseline to 6 months of follow-up, post-implant

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 学习椅:Bradley Knight, MD、Northwestern University
  • 学习椅:Michael Zile, MD、Medical University of South Carolina
  • 学习椅:Fred Weaver, MD、University of Southern California

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年1月29日

初级完成 (实际的)

2024年8月28日

研究完成 (实际的)

2025年2月17日

研究注册日期

首次提交

2020年10月19日

首先提交符合 QC 标准的

2020年10月19日

首次发布 (实际的)

2020年10月23日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月9日

最后验证

2025年5月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 360058-001

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅